Physician profile
Michael L Gross
NPI 1396712337
$5,219.93
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,478 · 2020: $139 · 2021: $1,224 · 2022: $108 · 2023: $118 · 2024: $153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $270.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $270.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arthrex, INC. | $4,491.00 | 2019-2021 | |
| Harmony Biosciences LLC | $133.81 | 2023-2024 | Wakix |
| Smith+Nephew, INC. | $107.43 | 2019 | |
| Depuy Synthes Sales INC. | $102.61 | 2019-2023 | Monovisc, Orthovisc |
| Encore Medical, LP | $94.82 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $44.50 | 2022 | |
| Stryker Corporation | $41.73 | 2024 | 1688, System 9 Cd Nxt |
| Octapharma USA, INC. | $38.58 | 2021-2022 | |
| Bioventus LLC | $35.35 | 2022 | |
| Lilly USA, LLC | $28.79 | 2019-2022 | |
| Abbott Laboratories | $28.12 | 2019 | |
| Fidia Pharma USA INC. | $23.08 | 2024 | Hymovis |
| Biocryst US Sales Co., LLC | $22.16 | 2024 | Orladeyo |
| Ferring Pharmaceuticals INC. | $16.19 | 2024 | Euflexxa |
| Actelion Pharmaceuticals US, INC. | $11.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Gross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.